65 results about "Anxiolytic" patented technology

The invention provides a Morinda officinalis extractive and a preparation method and an application. The invention provides a preparation method of an extract from a traditional Chinese medicine Radix Morindae officinalis. The invention provides preparation methods and structures of 12 new compounds in the extract (such as synanthrin type 10-21 polysaccharide and the like), and the molecular connection mode is as follows: alpha-D-glucopyranose-(1->2)-[beta-D-fructofuranose-(1->2)]8-19-beta-D-fructofuranose. The invention provides methods for preparing these compounds from Helianthus tuberosus, yacon and other plants. The invention provides a method for preparing the extract into a medicinal composition. The invention also provides applications of the extract used as an antidepressant and an anxiolytic.

The invention discloses an application of a P2X2 receptor agonist or a P2X2 receptor opening agent in preparation of anti-depression or anti-anxiety drugs. According to the present invention, experiment research results confirm that: the P2X2 receptor agonist or the P2X2 receptor opening agent has an anti-depression and / or anti-anxiety effect, such that the P2X2 receptor agonist or the P2X2 receptor opening agent can be used for preparing anti-depression or anti-anxiety drugs, and can be adopted to screen prevention and treatment target points of anti-depression and / or anti-anxiety drugs and screen early stage pre-warning and clinical diagnostic reagents of depression and / or anxiety so as to provide broad application prospects.

The invention relates to the field of medicine and discloses a Murraya paniculata leaf, a Murraya paniculata leaf extractive and new biological activity of part of a flavonoid mono compound extracted from Murraya paniculata leaves, namely discloses a Murraya paniculata leaf, a Murraya paniculata leaf extractive and the use of part of a flavonoid mono compound extracted from Murraya paniculata leaves in preparation of sedative and hypnotic drugs, anxiolytic drugs, anticonvulsive drugs or antimanic drugs, in particular to the use in preparation of sedative and hypnotic drugs.

Imidazo[1,2-a]pyridines of the formulae I and II:are disclosed. The compounds are useful to treat anxiety and insomnia. Pharmaceutical compositions and methods are also disclosed. A representative compound of the invention is:

Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.

Described herein are novel methods and formulations for reducing suicidality in human subjects. Such formulations and methods are a combination of lithium and one or more other CNS therapeutic agents such as anti-depressant, mood-stabilizing, anxiolytic, anticonvulsant, antipsychotic, anti-addictive, and appetite suppressant drugs.

PCT No. PCT / EP92 / 02981 Sec. 371 Date Jul. 14, 1994 Sec. 102(e) Date Jul. 14, 1994 PCT Filed Dec. 22, 1992 PCT Pub. No. WO93 / 12784 PCT Pub. Date Jul. 8, 1993The invention suggests a novel medical use of pure bilobalide or Ginkgo biloba extract with an increased bilobalide content as an anxiolytic or antidepressant.

The invention provides application of a substituted cinnamamide derivative to preparation of anxiolytic medicine. The substituted cinnamamide derivative uses a compound of a structure shown by a formula (I) or a pharmaceutically acceptable salt as a medicine active ingredient. The concrete formula is shown as the accompanying drawing; in the formula, R1 is -H, -OH, -F, -Cl, -Br, -I, -OCH3, -OCF3, -OCHF2, -OCH2F, -CF3, -CHF2, -CH2F, -CH3, -CH3CH2, -CF3CH2, -CN, -NO2, -NH2 or -COOR5; R2 is H, C1-C10 straight-chain alkyls, C3-C10 branch-chain alkyl groups, C3-C10 cyclic hydrocarbon groups, C1-C10 hydroxyalkyls or N-substituted piperazine derivative groups; or the R2 is a group forming a nafoxidine group, a piperidyl or a cyclohexylamine group with the adjacent X. The formula (I) is shown as the accompanying drawing.

Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided. A polymorph Form II:

The present invention relates to a method for screening a chemical compound for its potential as a sedative or anxiolytica. The invention also relates to a drug development method and to the use of a compound as identified by the screening method for the treatment, prevention or alleviation of anxiety, for inducing anaesthesia, pre-anaesthesia, muscle relaxation, or sedation, or for treatment, prevention or alleviation of fever cramps or status epilepticus in a subject.

A morphinan derivative represented by the following general formula (I):(wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.,R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group,Y binds to a carbon atom as a ring-constituting atom of R2,R3, R4, and R5 represent hydrogen; hydroxy, etc.,R6a and R6b represent hydrogen, etc.,R7 and R8 represent hydrogen, etc.,R9 and R10, which are the same or different, represent hydrogen, etc.,X represents O or CH2, andY represents C(═O)),a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.

Mixed inhibitors of aminopeptidase N and of neprilysine are described. Pharmaceutical compositions containing at least one of these compounds, used alone or in combination with morphine and derivatives thereof, endocannabinoids and inhibitors of the metabolism thereof, GABA derivatives such as gabapentin or pregabalin, duloxetine or methadone, can be used as an analgesic, anxiolytic, antidepressant or anti-inflammatory.